Exact Sciences to buy Genomic Health for $2.8 billion

FAN Editor

Operations at Exact Sciences

Source: Exact Sciences

Cancer diagnostics company Exact Sciences said on Monday it will buy health-care company Genomic Health for about $2.8 billion to bolster its cancer testing business.

Under terms of the deal, Genomic Health stockholders will receive $27.50 in cash and $44.50 in shares of Exact Sciences stock, for a total value of $72 per share.

Wisconsin-based Exact Sciences focuses on early detection of cancer, developing DNA-based tests to help diagnose colorectal cancer.

Free America Network Articles

Leave a Reply

Next Post

Stock futures trade cautiously to start a week with a Fed meeting, trade talks and jobs

There will be plenty of events to drive the markets this week. Continue Reading Below Investors are bracing for the busiest week of second-quarter earnings season, with 7 Dow members and 159 companies in the S&P 500, or almost one-third of the benchmark index, posting results. The three major U.S. […]